Smarter dosing for kids with superbug infections?
NCT ID NCT02694458
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether an early, computer-guided dosing strategy for vancomycin helps children with MRSA infections reach the right drug levels faster than the usual approach. 100 children aged 1 month to 16 years took part. The goal was to improve treatment effectiveness while avoiding toxic side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- vancomycin
- What this could lead to
- If successful, this approach could help children with MRSA get the right dose of vancomycin sooner, improving treatment and reducing side effects.
- What could go wrong
- This is a small, single-hospital study testing a dosing method, not a new drug. The strategy may not work for all children or in other hospitals.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METHICILLIN-RESISTANT STAPHYLOCOCCAL INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hôpital Necker-Enfants Malades
Paris, Paris, 75015, France